LEXICON PHARMACEUTICALS INC (LXRX)
US5288723027 - Common Stock
Taking everything into account, LXRX scores 2 out of 10 in our fundamental rating. LXRX was compared to 565 industry peers in the Biotechnology industry. LXRX may be in some trouble as it scores bad on both profitability and health. LXRX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year LXRX has reported negative net income.
In the past year LXRX has reported a negative cash flow from operations.
LXRX had negative earnings in 4 of the past 5 years.
LXRX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -67.39%, LXRX is doing worse than 64.53% of the companies in the same industry.
LXRX has a Return On Equity of -121.22%. This is comparable to the rest of the industry: LXRX outperforms 40.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.39% | ||
| ROE | -121.22% | ||
| ROIC | N/A |
ROA(3y)-64.59%
ROA(5y)-38.28%
ROE(3y)-118.18%
ROE(5y)-56.18%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 93.54%, LXRX belongs to the top of the industry, outperforming 94.65% of the companies in the same industry.
LXRX's Gross Margin has been stable in the last couple of years.
LXRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.54% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y-0.65%
2. Health
2.1 Basic Checks
LXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LXRX has been increased compared to 1 year ago.
LXRX has more shares outstanding than it did 5 years ago.
LXRX has a worse debt/assets ratio than last year.
2.2 Solvency
LXRX has an Altman-Z score of -8.49. This is a bad value and indicates that LXRX is not financially healthy and even has some risk of bankruptcy.
LXRX has a worse Altman-Z score (-8.49) than 72.91% of its industry peers.
LXRX has a Debt/Equity ratio of 0.56. This is a neutral value indicating LXRX is somewhat dependend on debt financing.
The Debt to Equity ratio of LXRX (0.56) is worse than 74.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.49 |
ROIC/WACCN/A
WACC11.47%
2.3 Liquidity
LXRX has a Current Ratio of 7.45. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
LXRX's Current ratio of 7.45 is fine compared to the rest of the industry. LXRX outperforms 70.59% of its industry peers.
A Quick Ratio of 7.43 indicates that LXRX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.43, LXRX is in the better half of the industry, outperforming 70.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.45 | ||
| Quick Ratio | 7.43 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 1.32% over the past year.
Looking at the last year, LXRX shows a very strong growth in Revenue. The Revenue has grown by 945.80%.
The Revenue for LXRX have been decreasing by -54.71% on average. This is quite bad
EPS 1Y (TTM)1.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)945.8%
Revenue growth 3Y-63.12%
Revenue growth 5Y-54.71%
Sales Q2Q%980.25%
3.2 Future
Based on estimates for the next years, LXRX will show a very strong growth in Earnings Per Share. The EPS will grow by 30.06% on average per year.
Based on estimates for the next years, LXRX will show a very strong growth in Revenue. The Revenue will grow by 222.40% on average per year.
EPS Next Y12.37%
EPS Next 2Y11.15%
EPS Next 3Y12.17%
EPS Next 5Y30.06%
Revenue Next Year788.75%
Revenue Next 2Y432.54%
Revenue Next 3Y307.33%
Revenue Next 5Y222.4%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
LXRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LXRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
LXRX's earnings are expected to grow with 12.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.15%
EPS Next 3Y12.17%
5. Dividend
5.1 Amount
LXRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LEXICON PHARMACEUTICALS INC
NASDAQ:LXRX (11/21/2024, 8:00:01 PM)
After market: 0.77 0 (-0.22%)0.7717
-0.04 (-4.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap278.96M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.39% | ||
| ROE | -121.22% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.54% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.45 | ||
| Quick Ratio | 7.43 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)1.32%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y12.37%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)945.8%
Revenue growth 3Y-63.12%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y